// App-Quantinova.ai

470 : High-dose TSLP decreases in vivo tumor burden in preclinical models of CRLF2 B-ALL

Researchers

Presenter

  • Caleb Ruiz-Jimenez

Principal Investigators

  • Jacqueline Coats

  • Cornelia Stoian

  • Ineavely Baez

  • Hossam Alkashgari

  • Andy Paz-Aldana

  • Hannah Choi

  • Roland Williams

  • Shadi Farzin Gohar

  • Sinisa Dovat

  • Kimberly Payne

Medical Centers

  • Loma Linda University, Loma Linda, CA

  • Pennsylvania State University College of Medicine, Hershey, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Solid malignancies

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Peptidase inhibitor 3

  • Interleukin-7

  • Janus kinase

  • Serine/threonine-protein kinase mTOR

  • Signal transducer and activator of transcription 5

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved